-
Savarirayan, R, Hoernschemeyer, DG, Ljungberg, M, Zarate, YA, Bacino, CA, Bober, MB, Legare, JM, Högler, W, Quattrin, T, Abuzzahab, MJ, et al.
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.
EClinicalMedicine
65:
102258
2023
view publication
-
Savarirayan, R, De Bergua, JM, Arundel, P, Salles, JP, Leiva-Gea, A, Irving, M, Saraff, V, McDevitt, H, Salcedo, M, Nicolino, MP, et al.
THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib.
Journal of the Endocrine Society
7(Supplement_1)
:
bvad114.1432
2023
view publication
-
Savarirayan, R, De Bergua, JM, Arundel, P, McDevitt, H, Cormier-Daire, V, Saraff, V, Skae, M, Delgado, B, Leiva-Gea, A, Salcedo, M, et al.
THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials.
Journal of the Endocrine Society
7(Supplement_1)
:
bvad114.1416
2023
view publication
-
Savarirayan, R, McDonnell, C, Hoernschemeyer, DG, Hove, HB, Zarate, YA, Bober, MB, Bacino, CA, Legare, JM, Högler, W, Quattrin, T, et al.
THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Journal of the Endocrine Society
7(Supplement_1)
:
bvad114.1408
2023
view publication
-
Savarirayan, R, De Bergua, JM, Arundel, P, Salles, JP, Saraff, V, Delgado, B, Leiva-Gea, A, McDevitt, H, Nicolino, MP, Rossi, M, et al.
OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study.
Journal of the Endocrine Society
7(Supplement_1)
:
bvad114.1525
2023
view publication